Connect with us

News

Pfizer, BioNTech COVID-19 Vaccine 90 Percent Effective

Published

on

Coronavirus 2

Pfizer and BioNTech COVID-19 Vaccine 90 Percent Effective

In what could be an end to the COVID-19 menace, Pfizer and Germany’s BioNTech latest vaccine has been found to be more than 90 percent effective in coronavirus.

The good news is that the vaccine could be available by the end of the year if authorities approve it.

Pfizer and BioNTech result was the first independent analysis of any COVID-19 vaccine in phase 3 trials— the final stage before commercial licensing. Out of the 43,000 trial participants, the small number who were infected enabled the independent evaluators to calculate the effectiveness after two doses.

“To me, this is the best possible outcome,” Ugur Sahin, co-founder and chief executive of BioNTech told the Financial Times, while Pfizer boss Albert Bourla said it was “a great day for science and humanity”.

The drug is expected to be submitted to authorities for emergency approval in the third week of November, ahead of other vaccine developers. Former vaccine frontrunner Moderna does not expect to have the trial data required to go for approval until November 25, while AstraZeneca’s partnership with the University of Oxford expects results by the end of this year.

Pfizer shares jumped almost 15 per cent in pre-market trading in New York, while Nasdaq-listed BioNTech rose 25 per cent.

The Pfizer results far exceed the US Food and Drug Administration’s criteria for approving a Covid-19 vaccine, which mandates an efficacy of at least 50 per cent in placebo-controlled trials. No vaccine is 100 per cent effective, according to the World Health Organization.

Pfizer and BioNTech said that up to 50m doses of the vaccine — which would be the first vaccine to use novel mRNA technology — could be manufactured this year, and a further 1.3bn doses produced in 2021.

Global equity markets rallied sharply after Pfizer’s announcement, led by travel and leisure companies that have been hit particularly hard by the coronavirus crisis.

British Airways parent IAG soared by a third in London, while Air France KLM jumped 30 per cent in Paris and Ryanair climbed 16 per cent in Dublin. Oil prices, which have been knocked by the pandemic’s effects on demand for fuel, also added to earlier gains. Brent crude, the international standard, was up 8.5 per cent at $42.83 in recent trading.

The US has secured orders for 100m doses of the shot, with an option to acquire another 500m, while the UK has an agreement to procure 30m doses. A deal for the supply of 200m doses to the EU is under negotiation.

Mr Sahin said BioNTech and Pfizer would “use a fair approach” when it came to distributing the first doses of the vaccine, adding that they would prioritise deliveries to countries where it had been approved for use.

“This looks really good,” said Ian Jones, professor of virology at the University of Reading. “Of all the current vaccine currently in development the BioNTech product always looked like the most bang-per-buck as it is entirely focused on the part of the virus that binds to the human cell, the receptor binding domain.”

“The questions around its use were about the ability to manufacture at scale and the possible toxicity associated with a directly injected RNA product. The trial data show excellent results on both of those areas, really impressive protection and no reported adverse events,” he added.

Brendan Wren, professor of vaccinology at the London School of Hygiene and Tropical Medicine, said 90 per cent efficacy was “excellent for a new vaccine”, while adding a note of caution. “It is a case of ‘so far so good’ but more confirmatory safety and efficacy studies are required.”

BioNTech’s Mr Sahin said he expected the vaccine’s immune response to last for “at least one year”, adding that the vaccine-induced antibodies were shown to block about 20 different mutations of Sars-Cov-2. “There’s a very low likelihood that a [mutation of] the virus can overcome the immune response,” he predicted.

CEO/Founder Investors King Ltd, a foreign exchange research analyst, contributing author on New York-based Talk Markets and Investing.com, with over a decade experience in the global financial markets.

News

Npower Batch A and B Beneficiaries Can Now Access NEXIT Portal

Published

on

npower latest news

Exited Npower beneficiaries of batches A and B can now access the NEXIT Portal, according to Nneka Ikem, the Special Assistant, Media & Publicity to the Minister of Humanitarian Affairs, Disaster Management and Social Development, Hajiya Sadiya Farouq.

Here is how to register on the NEXIT

1. Visit the Official NEXIT Portal by clicking here

2. Then enter the email address you used for your Npower application.

3. Create and set up a new password on the NEXIT Portal

4. Now enter your name as registered on your Npower profile

5. Kindly input your Bank Verification Number

6. Finally, agree to the terms and policy and hit the submit button.

The next stage is to re-enter your email address on the activation page. Once that is done, go to your email and click the activation link sent to your e-mail.

Now login into the NEXIT portal with your credientials and complete the questionaire.

The portal was introduced to engage exited Npower beneficiaries through the Central Bank of Nigeria’s job options.

On Monday Hajiya Sadiya Farouq said “The NEXIT portal is to determine the suitability of the beneficiaries for the CBN affiliated programs and is dependent on meeting the criteria and conditions set by the CBN for the said programs”.

“The Federal Government of Nigeria is very proud of the milestones you have achieved during your period of service to the nation. As we prepare to exit into prospective endeavors, we are confident that you will be able to channel all you have learnt over the years into successful ventures that will improve the economy of the country and create further opportunities for you and other citizens.

“Chasing a dream requires effort, passion and hard work which you are now halfway through. I congratulate you and wish you a very successful future”.

Continue Reading

News

Pfizer, BioNTech COVID-19 Vaccine to be Available to UK Resident on Dec 7

Published

on

The United Kingdom is planning to approve Pfizer and BioNTech COVID-19 vaccine in a few days, according to government officials.

According to the officials, deliveries of the COVID-19 vaccine would begin a few hours after authorisation and the first injections could take place on December 7.

UK Prime Minister, Boris Johnson, has named Nadhim Zahawi, the current junior business minister, as the minister responsible for the deployment of the vaccines.

Britain said on Nov. 20 it had formally asked its medical regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), to evaluate the Pfizer-BioNTech COVID-19 vaccine for its suitability, the first step in making it available outside the United States.

The UK ordered 40 million doses of the two-shot product, which the preliminary data showed to be more than 95 percent effective.

Continue Reading

News

Npower News: CBN Job Options for Exited Npower Beneficiaries

Published

on

The Ministry of Humanitarian Affairs, Disaster Management and Social Development in collaboration with the Central Bank of Nigeria has launched an online portal called N-Exit to enable exited Npower Beneficiarieas apply for Central Bank of Nigeria Empowerement Options.

The ministry stated a statement signed by Bashir Nura Alkali, the Permanent Secretary of the Ministry.

Sadiya Umar Farouq, the Minister of Humanitarian Affairs, Disaster Management and Social Development, urged interested exited npower beneficiaries to log on to the portal and add other additional information required for placements into the CBN intervention options.

The minister also stated that the NEXIT Portal will determine the suitability of the interested exited beneficiaries of Npower for teh CBN affiliate programes.

The statement reads, “The NEXIT portal is to determine the suitability of the beneficiaries for the CBN affiliated programs and is dependent on meeting the criteria and conditions set by the CBN for the said programs”.

“The Federal Government of Nigeria is very proud of the milestones you have achieved during your period of service to the nation. As we prepare to exit into prospective endeavors, we are confident that you will be able to channel all you have learnt over the years into successful ventures that will improve the economy of the country and create further opportunities for you and other citizens.

“Chasing a dream requires effort, passion and hard work which you are now halfway through. I congratulate you and wish you a very successful future”.

Continue Reading

Trending